NEW HAVEN, Conn., Nov 27, 2006 (BUSINESS WIRE) -- Cenestra Health, a privately-held, New Haven, Conn. based biotech company has entered into a distribution agreement with First Vitality International, LTD, to distribute its high purity Omega 3 supplement, Omax3(TM) The Ultra-Pure Omega 3 Supplement(TM), in the United Kingdom and European Union. Omax3 is a pharmaceutical grade health supplement that is currently available over-the-counter, without prescription, in the United States.
Omax3(TM) delivers 1.5 grams of essential fatty acids per serving. Each softgel is over 91% pure Omega-3s and third party tested to ensure unsurpassed freshness, quality and purity.
For additional information on the news that is the subject of this release, contact Ann Coric M.D. or visit www.Omax3.com. Omax3(TM) and The Ultra-Pure Omega 3 Supplement(TM) are trademarks of Cenestra Health.
About Cenestra, LLC: Cenestra, LLC (D/B/A Cenestra Health) is a New Haven, Conn. based company founded to formulate and provide "best-in-class" natural products, which are based on sound research, manufactured to pharmaceutical grade quality and can be confidently recommended by physicians and healthcare professionals to their patients. Cenestra Health consultants include physicians and scientists from Yale University School of Medicine.
About First Vitality International, LTD: First Vitality is the largest internet supplier of pharmaceutical grade Omega 3 supplements in the UK and is located in Guernsey, Channel Islands, United Kingdom. First Vitality's trade division supplies specialist Omega supplement solutions to Independent Health stores, Pharmacies, and CAM practitioners. First Vitality is one of the most comprehensive information resources on the Internet for complementary nutritional medicine, with hundreds of pages of health data and research available at www.1stvitality.com.